Business Context and Reporting Period
Company: Orthofix Medical Inc. (OFIX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Orthofix is a global medical technology company providing solutions for musculoskeletal pathologies. Operations are managed through two reporting segments: Global Spine (84% of 2025 net sales) and Global Limb Reconstruction (16% of 2025 net sales). The company completed a "merger of equals" with SeaSpine Holdings Corporation in January 2023.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Net Sales | $822.3 million | $799.5 million | +2.9% |
| Gross Profit | $566.0 million | $545.9 million | +3.7% |
| Gross Margin | 68.8% | 68.3% | +0.5 pts |
| Operating Loss | $(81.4) million | $(84.6) million | Improvement |
| Net Loss | $(92.2) million | $(126.0) million | Improvement |
| Net Loss Per Share (Basic/Diluted) | $(2.33) | $(3.30) | Improvement |
| Operating Cash Flow | $33.3 million | $25.8 million | +29.3% |
| Free Cash Flow | $(1.3) million | $(9.1) million | Improvement |
| Cash and Cash Equivalents | $82.0 million | $83.2 million | -1.4% |
| Total Debt (Long-term) | $157.4 million | $157.0 million | Flat |
Note: Pro forma net sales excluding the discontinued M6 product lines were $811.9 million, representing a 4.1% increase on a constant currency basis.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 2.9% year-over-year. Global Spine sales grew 1.8%, driven by a 5.9% increase in Bone Growth Therapies. Global Limb Reconstruction sales grew 8.4% (5.3% constant currency), with U.S. sales up 15.8%.
- Discontinuation of M6 Product Lines: In February 2025, the company announced the discontinuation of the M6 artificial cervical and lumbar disc product lines to focus on more profitable opportunities. This resulted in a $13.0 million decrease in sales from these lines and significant impairment charges totaling approximately $31.8 million (including inventory reserves and asset impairments).
- Profitability Improvement: Net loss narrowed by approximately $33.8 million compared to 2024. This was driven by a reduction in interest expense (due to refinancing in late 2024) and a decrease in the amortization of inventory fair value step-up from the SeaSpine merger.
- Expense Increases: Sales, General, and Administrative (SG&A) expenses increased by $21.8 million, primarily due to $17.6 million in legal costs related to arbitration with former executives and securities class action litigation, and $10.1 million in restructuring and impairment costs related to the M6 discontinuation.
- Debt Refinancing: In November 2024, the company entered a new $275.0 million secured credit agreement, replacing prior financing. As of December 31, 2025, $160.0 million was drawn under the Initial Term Loan.
Guidance, Outlook, and Risks
Management Commentary:
- Management continues to integrate legacy businesses from the SeaSpine merger, aiming to achieve synergies.
- Strategic focus remains on organic and inorganic innovation, particularly in spinal implants, biologics, and the 7D FLASH Navigation System.
- The company expects to continue investing in the Fitbone intramedullary limb lengthening platform and the TrueLok external fixation system.
Key Risks and Contingencies:
- Legal Proceedings: The company is facing arbitration claims from three former executives (CEO, CFO, CLO) terminated in September 2023. An interim award of $11.8 million was issued to the former CEO in January 2026, with the company maintaining an accrual of $18.3 million. Additionally, consolidated securities class action and derivative lawsuits are pending.
- Regulatory Reclassification: An FDA panel recommended reclassifying bone growth stimulator devices from Class III to Class II, which could increase competition in this category.
- Supply Chain and Inventory: The company maintains high inventory levels, creating risks of obsolescence and expiration, particularly for biologics. Inventory reserves increased by $4.6 million in 2025, partly due to the M6 discontinuation.
- Debt Covenants: The company must maintain a maximum total debt-to-EBITDA leverage ratio of 4.0x and maintain $15.0 million of unrestricted cash. Management believes it is in compliance.
Investor Verification Checklist
- Legal Accruals: Verify the final resolution and total cost of the arbitration claims against former executives, specifically the final order for Keith Valentine and the status of claims by John Bostjancic and Patrick Keran.
- M6 Discontinuation Impact: Confirm the full extent of inventory write-offs and asset impairments related to the M6 product lines and the timeline for the complete exit of these products.
- Debt Facility Utilization: Monitor the utilization of the $65.0 million Term B Loan (drawn in January 2026) and compliance with the 4.0x debt-to-EBITDA covenant.
- Regulatory Status: Track the final FDA decision regarding the reclassification of bone growth stimulator devices and its potential impact on the Bone Growth Therapies segment.
- Inventory Levels: Review future inventory turnover ratios and reserve requirements, given the high levels of consigned and biologics inventory.